Galmed Pharmaceuticals Ltd. (GPH.F)

0.3540 -0.0160 (-4.32%) At close: 08:00AM CEST

Galmed Pharmaceuticals Ltd.

16 Abba Hillel Road
Ramat Gan 5250608
Israel
972 3 693 8448
https://www.galmedpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 3

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Allen Baharaff	Co-Founder, President, CEO & Chairman	904.33k	N/A	1965
Mr. Doron Cohen	Chief Financial Officer	228.82k	N/A	1967
Mr. Guy Nehemya	COO & Data Protection Officer	267.01k	N/A	1985
Mr. Yohai Stenzler CPA	Chief Accounting Officer	270.3k	N/A	1983
Dr. Liat Hayardeny	Chief Scientific Officer	44.59k	N/A	1967
Ms. Yael Hollander	Vice President of Legal Affairs & Strategy	124.85k	N/A	1983
Ms. Shani Ganon	Human Resources Manager	N/A	N/A	N/A
Dr. Tali Gorfine	Medical Consultant	188.62k	N/A	1970

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Corporate Governance

Galmed Pharmaceuticals Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.